Abstract
COX-inhibiting nitric oxide donators (CINODs) are a new class of drugs in development for the treatment of acute and chronic pain. They comprise a COX-inhibiting moiety linked to a nitric-oxide-donating component and are designed to provide an innovative mechanism of action of balanced COX inhibition and controlled nitric oxide donation. Through these pathways, CINODs should provide analgesic and anti-inflammatory efficacy, while offering gastrointestinal safety through the tissue-protective effects of nitric oxide donation. AZD3582 [4-(nitrooxy)butyl-(2S)-2-(6-methoxy-2-naphthyl)propanoate] is the first agent in the CINOD class to enter extensive clinical development. Pre-clinical studies demonstrate that AZD3582 has a superior gastrointestinal safety profile to naproxen, while demonstrating analgesic and anti-inflammatory efficacy. In healthy human volunteers, AZD3582 caused little gastrointestinal damage compared with equimolar doses of naproxen. Studies to evaluate the longer-term gastrointestinal safety of AZD3582, alongside its efficacy in alleviating chronic and acute pain, are ongoing.
Similar content being viewed by others
REFERENCES
Agrawal, N. M., Van Kerckhove, H. E., Erhardt, L. J., et al. (1995). Misoprostol coadministered with diclofenac for prevention of gastroduodenal ulcers. A one-year study, Dig. Dis. Sci. 40, 1125–1131.
Asako, H., Kubes, P., Wallace, J., et al. (1992). Indomethacin-induced leukocyte adhesion in mesenteric venules: role of lipoxygenase products, Am. J. Physiol. 262, G903–G908.
Berge, O.-G., Raud, J. and Hoogstraate, J. (2002). AZD3582 reduces pain, inflammation and fever in animals, Ann. Rheum. Dis. 61 (Suppl. 1), 286.
Berndt, G., Grosser, N., Hoogstraate, J., et al. (2002). A common pathway for nitric oxide release from AZD3582 and glyceryl trinitrate, Ann. Rheum. Dis. 61 (Suppl. 1), 269.
Blower, A. L., Brooks, A., Fenn, G. C., et al. (1997). Emergency admissions for upper gastrointestinal disease and their relation to NSAID use, Aliment. Pharmacol. Ther. 11, 283–291.
Bombardier, C., Laine, L., Reicin, A. S., et al. (2000). Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group, New Engl. J. Med. 343, 1520–1528.
Bredt, D. S. (1999). Endogenous Nitric oxide synthesis: biological functions and pathophysiology, Free Radic. Res. 31, 577–596.
Davies, N., Roseth, A., Appleyard, C., et al. (1997). NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects, Aliment. Pharmacol. Ther. 11, 69–79.
Del Soldato, P., Foschi, D., Benoni, G., et al. (1986). Oxygen free radicals interact with indomethacin to cause gastrointestinal injury, Agents Actions 17, 484–488.
Elliott, S. L., Yeomans, N. D., Buchanan, R. R., et al. (1994). Efficacy of 12 months' misoprostol as prophylaxis against NSAID-induced gastric ulcers. A placebo-controlled trial, Scand. J. Rheumatol. 23, 171–176.
Estes, L. L., Fuchs, D. W. and Heaton, A. H. (1993). Gastric ulcer perforation associated with the use of injectable ketorolac, Ann. Pharmacother. 27, 42–43.
Fiorucci, S., Antonelli, E., Santucci, L., et al. (1999). Gastrointestinal safety of nitric oxide-derived aspirin is related to inhibition of ICE-like cysteine proteases in rats, Gastroenterology 116, 1089–1106.
Fiorucci, S., Santucci, L., Gresele, P., et al. (2003). Gastrointestinal safety of NO-aspirin (NCX-4016) in healthy human volunteers: a proof of concept endoscopic study, Gastroenterology 124, 600–607.
Gana, T. J., Huhlewych, R. and Koo, L. (1987). Focal gastric mucosal blood flow in aspirin-induced ulceration, Ann. Surg. 205, 399–403.
Geis, G. S., Stead, H., Wallemark, C. B., et al. (1991). Prevalence of mucosal lesions in the stomach and duodenum due to chronic use of NSAID in patients with rheumatoid arthritis or osteoarthritis and interim report on prevention by misoprostol of diclofenac associated lesions, J. Rheumatol. 28, 11–14.
Goldstein, J. L., Correa, P., Zhao, W. W., et al. (2001). Reduced incidence of gastroduodenal ulcers with celecoxib, a novel cyclooxygenase-2 inhibitor, compared to naproxen in patients with arthritis, Am. J. Gastroenterol. 96, 1019–1027.
Hawkey, C., Jones, J. I., Atherton, C. T., et al. (2003). Gastrointestinal safety of AZD3582: a new chemical entity with a novel multi-pathway mechanism of action, Gut (in press).
Hawkey, C., Karateev, D., Codreanu, C., et al. (2002). Improved upper gastrointestinal (UGI) safety and tolerability of a new coxib, COX189 compared with ibuprofen in osteoarthritis patients, Ann. Rheum. Dis. 61 (Suppl. 1), 126.
Hawkey, C. J., Laine, L., Harper, S. E., et al. (2001). Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials, Aliment. Pharmacol. Ther. 15, 1593–1601.
Henry, D., Dobson, A. and Turner, C. (1993). Variability in the risk of major gastrointestinal compli-cations from nonaspirin nonsteroidal anti-inflammatory drugs, Gastroenterology 105, 1078–1088.
Kelly, J. P., Kaufman, D. W., Jurgelon, J. M., et al. (1996). Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered products, Lancet 348, 1413–1416.
Kitahora, T. and Guth, P. H. (1987). Effect of aspirin plus hydrochloric acid on the gastric mucosal microcirculation, Gastroenterology 93, 810–817.
Kubes, P., Suzuki, M. and Granger, D. N. (1991). Nitric oxide: an endogenous modulator of leukocyte adhesion, Proc. Natl. Acad. Sci. USA 88, 4651–4655.
Laine, L. (1996). Nonsteroidal anti-inflammatory drug gastropathy, Gastrointest. Endosc. Clin. N. Am. 6, 489–504.
Laine, L. (2001). Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient, Gastroenterology 120, 594–606.
Lanza, F. L., Rack, M. F., Simon, T. J., et al. (1999). Specific inhibition of cyclooxygenase-2 with MK-0966 is associated with less gastroduodenal damage than either aspirin or ibuprofen, Aliment. Pharmacol. Ther. 13, 761–767.
Lichtenberger, L. M. (1995). The hydrophobic barrier properties of gastrointestinalmucus, Annu. Rev. Biochem. 57, 565–583.
McCarthy, D. M. (1989). Nonsteroidal anti-inflammatory drug-induced ulcers: management by traditional therapies, Gastroenterology 96, 662–674.
Melo Gomes, J. A., Roth, S. H., Zeeh, J., et al. (1993). Double-blind comparison of efficacy and gastroduodenal safety of diclofenac/ misoprostol, piroxicam and naproxen in the treatment of osteoarthritis, Ann. Rheum. Dis. 52, 881–885.
Moncada, S. and Erusalimsky, J. D. (2002). Does nitric oxide modulate mitochondrial energy generation and apoptosis?, Nature Rev. Mol. Cell. Biol. 3, 214–220.
Öjteg, G., Hällgren, A. and Hoogstraate, J. (2002). AZD3582, a COX-inhibiting nitric oxide donator (CINOD), is gastroprotectivein the rat, Ann. Rheum. Dis. 61 (Suppl. 1), 288.
O'Laughlin, J. C., Hoftiezer, J. W. and Ivey, K. J. (1981). Effect of aspirin on the human stomach in normals: endoscopic comparison of damage produced one hour, 24 hours and 2 weeks after administration, Scand. J. Gastroenterol. Suppl. 67, 211–214.
Radomski, M. W., Palmer, R. M. and Moncada, S. (1987). Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium, Lancet ii, 1057–1058.
Roth, S. H., Bennett, R., Caldron, P., et al. (1994). A longtermendoscopic evaluation of patients with arthritis treated with nabumetone vs naproxen, J. Rheumatol. 21, 1118–1123.
Satoh, H., Guth, P. H. and Grossman, M. I. (1982). Role of food in gastrointestinalulceration produced by indomethacin in the rat, Gastroenterology 83, 210–215.
Shorrock, C. J., Prescott, R. J. and Rees, W. D. (1990). The effects of indomethacinon gastroduodenal morphology and mucosal pH gradient in the healthy human stomach, Gastroenterology 99, 334–339.
Silverstein, F. E., Faich, G., Goldstein, J. L., et al. (2000). Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: A randomized controlled trial, J. Am. Med. Ass. 284, 1247–1255.
Silverstein, F. E., Graham, D. Y., Senior, J. R., et al. (1995). Misoprostol reduces serious gastrointesti-nal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlledtrial, Ann. Intern. Med. 123, 241–249.
Simon, L. S., Lanza, F. L., Lipsky, P. E., et al. (1998). Preliminary study of the safety and efficacy of SC-58635, a novel cyclooxygenase 2 inhibitor, Arthritis. Rheum. 41, 1591–1602.
Simon, L. S., Weaver, A. L., Graham, D. Y., et al. (1999). Anti-inflammatory and upper gastrointesti-nal effects of celecoxib in rheumatoid arthritis. A randomized controlled trial, J. Am. Med. Ass. 282, 1921–1928.
Singh, G. and Triadafilopoulos, G. (1999). Epidemiology of NSAID induced gastrointestinal complications, J. Rheumatol. 26, 18–24.
Soll, A. H., Weinstein, W. M., Kurata, J., et al. (1991). Nonsteroidal anti-inflammatory drugs and peptic ulcer disease, Ann. Intern. Med. 114, 307– 319.
Somasundaram, S., Sigthorsson, G., Simpson, R. J., et al. (2000). Uncoupling of intestinal mitochon-drial oxidative phosphorylationand inhibition of cyclooxygenaseare required for the development of NSAID-enteropathy in the rat, Aliment. Pharmacol. Ther. 14, 639–650.
Tramer, M. R., Moore, R. A., Reynolds, D. J. M., et al. (2000). Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use, Pain 85, 169–182.
Vane, J. R. (1971). Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs, Nature New. Biol. 231, 232–235.
Wallace, J. L. and Tigley, A. W. (1995). Review article: new insights into prostaglandins and mucosal defence, Aliment. Pharmacol. Ther. 9, 227–235.
Wallace, J. L., McKnight, W., Reuter, B. K., et al. (2000). NSAID-induced gastric damage in rats: requirement for inhibition of both cyclooxygenase 1 and 2, Gastroenterology 119, 706–714.
Wallace, J. L., Ojteg, G., Andersson L. I., et al. (2003). AZD3582 produces fewer and smaller gastric ulcers than naproxen in the rat refeeding model, Ann. Rheum. Dis. 62 (Suppl. 1), 380.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jonzon, B., Bjarnason, I., Hawkey, C. et al. The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers. Inflammopharmacology 11, 437–444 (2003). https://doi.org/10.1163/156856003322699618
Issue Date:
DOI: https://doi.org/10.1163/156856003322699618